The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Omega-9 fatty acids are the differentiating fatty acid in the newest ILE on the US market. Clinicians are challenged to determine the most appropriate ILE for their patient. To do so it is essential to have a strong understanding of the attributes of the key fatty acids: omega- 3, 6 and 9 and the literature that support their safety and efficacy. This webinar will focus on providing the clinician an understanding of omega-9 fatty acids and the literature that supported its FDA approval in ILE products.
Learning Objectives:
Identify the characteristics of omega-9 fatty acids
Outline how omega-9 fatty acids differ from omega- 3 and 6 fatty acids and what benefit or disadvantage they may bring to an ILE
Summarize the clinical evidence supporting the efficacy and safety of the omega-9 fatty containing ILEs
Todd
Canada,
PharmD, BCNSP, BCCCP, FASHP, FTSHP,
Nutrition Support Team Coordinator,
University of Texas MD Anderson Cancer Center, Division of Pharmacy, Houston, TX